Comparing Principia Biopharma (PRNB) and G1 Therapeutics (GTHX)

Share on StockTwits

Principia Biopharma (NASDAQ:PRNB) and G1 Therapeutics (NASDAQ:GTHX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, institutional ownership, earnings and profitability.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Principia Biopharma and G1 Therapeutics, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Principia Biopharma 0 0 5 0 3.00
G1 Therapeutics 0 1 6 1 3.00

Principia Biopharma presently has a consensus price target of $43.50, suggesting a potential upside of 36.28%. G1 Therapeutics has a consensus price target of $66.00, suggesting a potential upside of 191.91%. Given G1 Therapeutics’ higher probable upside, analysts clearly believe G1 Therapeutics is more favorable than Principia Biopharma.

Insider and Institutional Ownership

82.1% of Principia Biopharma shares are owned by institutional investors. Comparatively, 73.5% of G1 Therapeutics shares are owned by institutional investors. 29.0% of Principia Biopharma shares are owned by company insiders. Comparatively, 15.9% of G1 Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Principia Biopharma and G1 Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Principia Biopharma N/A N/A N/A
G1 Therapeutics N/A -28.35% -27.19%

Earnings & Valuation

This table compares Principia Biopharma and G1 Therapeutics’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Principia Biopharma $69.14 million 11.02 $18.17 million $0.57 56.00
G1 Therapeutics N/A N/A -$85.29 million ($2.56) -8.83

Principia Biopharma has higher revenue and earnings than G1 Therapeutics. G1 Therapeutics is trading at a lower price-to-earnings ratio than Principia Biopharma, indicating that it is currently the more affordable of the two stocks.

Summary

Principia Biopharma beats G1 Therapeutics on 8 of the 11 factors compared between the two stocks.

About Principia Biopharma

Principia Biopharma Inc., a late-stage biopharmaceutical company, focuses on developing novel therapies for immunology and oncology. The company is developing PRN1008, an inhibitor that is in Phase III clinical trial for the treatment of pemphigus, a chronic skin disease, as well as in Phase II clinical trial to treat immune thrombocytopenic purpura. It is also developing PRN2246/SAR442168, an inhibitor, which has completed Phase I clinical trial for treating multiple sclerosis (MS) and other central nervous system (CNS) diseases; PRN1371, a drug candidate that is in Phase I clinical trial for the treatment of solid tumors; and oral small molecule inhibitors of the immunoproteasome. The company has a collaboration agreement with Genzyme Corporation to develop relapsing and progressive MS and other diseases of the CNS. Principia Biopharma Inc. was incorporated in 2008 and is headquartered in South San Francisco, California.

About G1 Therapeutics

G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase Ib/II clinical trials for patients with extensive-stage small cell lung cancer, as well as Phase II clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; lerociclib, an oral CDK4/6 inhibitor that is in Phase Ib/IIa clinical trials for the treatment of breast cancer and in Phase Ib/II clinical trial for non-small cell lung cancer; and G1T48, an oral selective estrogen receptor degrader, which is in Phase I clinical trial. The company was founded in 2008 and is headquartered in Research Triangle Park, North Carolina.

Receive News & Ratings for Principia Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Principia Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Mooncoin  Trading 22.2% Higher  This Week
Mooncoin Trading 22.2% Higher This Week
Comparing Principia Biopharma  and G1 Therapeutics
Comparing Principia Biopharma and G1 Therapeutics
Brokerages Anticipate Quaker Chemical Corp  to Post $1.55 EPS
Brokerages Anticipate Quaker Chemical Corp to Post $1.55 EPS
Walmart Inc  Insider John R. Furner Sells 10,000 Shares
Walmart Inc Insider John R. Furner Sells 10,000 Shares
Level Brands  Announces Quarterly  Earnings Results
Level Brands Announces Quarterly Earnings Results
Brokerages Set Airbus SE  Price Target at $128.88
Brokerages Set Airbus SE Price Target at $128.88


© 2006-2019 Ticker Report